Uni-Logo
ZHG-Logo
Zentrum für Humangenetik Bremen

Universität Bremen, Leobener Str. ZHG, D-28359 Bremen




Wir über uns Mitarbeiter Kontakt Genetische Beratung Diagnostik Forschung Publikationen Lehre Schulen
News Links Home Haftungsausschluss Impressum Research Disclaimer                
   

Publikationen
Publikationen der letzten 5 Jahre (Publications of the last 5 years)


Ältere Publikationen sind im Archiv zu finden.
Older publications may be found in the archive.


2015
  • Holzmann C, Markowski DN, Bartnitzke S, Koczan D, Helmke BM, Bullerdiek J (2015). A rare coincidence of different types of driver mutations among uterine leiomyomas (UL). Mol Cytogenet 8:76.

  • Markowski DN, Holzmann C, Bullerdiek J (2015). Genetic alterations in uterine fibroids - a new direction for pharmacological intervention? Expert Opin Ther Targets 21:1-10.

  • Milting H, Klauke B, Christensen AH, Müsebeck J, Walhorn V, Grannemann S, Münnich T, Šarić T, Rasmussen TB, Jensen HK, Mogensen J, Baecker C, Romaker E, Laser KT, zu Knyphausen E, Kassner A, Gummert J, Judge DP, Connors S, Hodgkinson K, Young TL, van der Zwaag PA, van Tintelen JP, Anselmetti D (2015)(online 2014). The TMEM43 Newfoundland mutation p.S358L causing ARVC-5 was imported from Europe and increases the stiffness of the cell nucleus. Eur Heart J:36(14):872-881.

  • Spiekermann M, Belge G, Winter N, Ikogho R, Balks T, Bullerdiek J, Dieckmann KP (online 2014). MicroRNA miR-371a-3p in serum of patients with germ cell tumours: evaluations for establishing a serum biomarker. Andrology 3:78-84.

  • Spiekermann M, Dieckmann KP, Balks T, Bullerdiek J, Belge G (2015). Is relative quantification dispensable for the measurement of microRNAs as serum biomarkers in germ cell tumors? Anticancer Res 35:117-121.

  • Vulto-van Silfhout AT, Nakagawa T, Bahi-Buisson N, Haas SA, Hu H, Bienek M, Vissers LE, Gilissen C, Tzschach A, Busche A, Müsebeck J, Rump P, Mathijssen IB, Avela K, Somer M, Doagu F, Philips AK, Rauch A, Baumer A, Voesenek K, Poirier K, Vigneron J, Amram D, Odent S, Nawara M, Obersztyn E, Lenart J, Charzewska A, Lebrun N, Fischer U, Nillesen WM, Yntema HG, Järvelä I, Ropers HH, de Vries BB, Brunner HG, van Bokhoven H, Raymond FL, Willemsen MA, Chelly J, Xiong Y, Barkovich AJ, Kalscheuer VM, Kleefstra T, de Brouwer AP. (2015). Variants in CUL4B are Associated with Cerebral Malformations. Hum Mutat 36:106-117.


2014
  • Drosch M, Schmidt N, Markowski DN, Zollner TM, Koch M, Bullerdiek J (2014). The CD24hi smooth muscle subpopulation is the predominant fraction in uterine fibroids. Mol Hum Reprod 20:664-676.

  • Holzmann C, Markowski, DN, Koczan D, Helmke BM, Bullerdiek J. (2014). Genome-wide acquired uniparental disomy as well as chromosomal gains and losses in an uterine epithelioid leiomyoma. Mol Cytogenet 7:19.

  • Holzmann C, Markowski DN, Koczan D, Küpker W, Helmke BM, Bullerdiek J (2014). Cytogenetically normal uterine leiomyomas without MED12-mutations - a source to identify unknown mechanisms of the development of uterine smooth muscle tumors. Mol Cytogenet 7: 88.
  • Klemke M, Müller MH, Wosniok W, Markowski DN, Nimzyk R, Helmke BM, Bullerdiek J (2014). Correlated expression of HMGA2 and PLAG1 in thyroid tumors, uterine leiomyomas and experimental models. PLoS One 9:e88126.

  • Markowski DN, Helmke BM, Bartnitzke S, Löning T, Bullerdiek J (2014). Uterine fibroids: do we deal with more than one disease? Int J Gynecol Pathol 33: 568-572.
  • Markowski DN, Tadayyon M, Bartnitzke S, Belge G, Helmke BM, Bullerdiek J (2014). Cell cultures in uterine leiomyomas: Rapid disappearance of cells carrying MED12 mutations. Genes Chromosomes Cancer 53:317-323.

  • Thies HW, Nolte I, Wenk H, Mertens F, Bullerdiek J, Markowski DN (2014)(online 2013). Permanent activation of HMGA2 in lipomas mimics its temporal physiological activation linked to the gain of adipose tissue. Obesity (Silver Spring) 22:141-150.


2013
  • Drosch M, Bullerdiek J, Zollner TM, Prinz F, Koch M, Schmidt N (2013). A novel mouse model that closely mimics human uterine leiomyomas. Fertil Steril 99:927-935.

  • Gillis AJ, Rijlaarsdam MA, Eini R, Dorssers LC, Biermann K, Murray MJ, Nicholson JC, Coleman N, Dieckmann KP, Belge G, Bullerdiek J, Xu T, Bernard N, Looijenga LH (2013). Targeted serum miRNA (TSmiR) test for diagnosis and follow-up of (testicular) germ cell cancer patients: A proof of principle. Mol Oncol 7:1083-1092.

  • Markowski DN, Bullerdiek J (2013). Chromothripsis in uterine leiomyomas. N. Engl. J. Med. 369: 2160.

  • Markowski DN, Huhle S, Nimzyk R, Stenman G, Löning T, Bullerdiek J (2013). MED12 mutations occurring in benign and malignant mammalian smooth muscle tumors. Genes Chromosomes Cancer 52:297-304.

  • Markowski DN, Nimzyk R, Belge G, Löning T, Helmke BM, Bullerdiek J. (2013). Molecular topography of the MED12-deleted region in smooth muscle tumors:  a possible link between non B-DNA structures and hypermutability. Mol Cytogenet 6(1):23.

  • Markowski DN, Thies HW, Gottlieb A, Wenk H, Wischnewsky M, Bullerdiek J (2013). HMGA2 expression in white adipose tissue linking cellular senescence with diabetes. Genes Nutr. 8:449-456.
  • Müller MH, Drieschner N, Focken T, Bartnitzke S, Winter N, Klemke M, Bullerdiek J (2013). HMGA2 expression in the PC-3 prostate cancer cell line is autonomous of growth factor stimulation. Anticancer Res 33:3069-3078.


2012

  • Belge G, Dieckmann KP, Spiekermann M, Balks T, Bullerdiek J (2012). Serum levels of microRNAs miR-371-3: A novel class of serum biomarkers for testicular germ cell tumors? Eur Urol 61:1068-1069.

  • Bullerdiek J, Flor I. (2012). Exosome-delivered microRNAs of "chromosome 19 microRNA cluster" as immunomodulators in pregnancy and tumorigenesis. Mol Cytogenet 5:27.

  • Dieckmann, KP, Spiekermann M, Balks T, Flor I, Löning T, Bullerdiek J, Belge G (2012). MicroRNAs miR-371-3 in serum as diagnostic tools in the management of testicular germ cell tumours. Br J Cancer 107:1754-1760.

  • Flor I, Bullerdiek J (2012). The dark side of a success story: microRNAs of the C19MC cluster in human tumours. J Pathol 227:270-274.

  • Flor I, Neumann A, Freter C, Helmke BM, Langenbuch M, Rippe V, Bullerdiek J (2012). Abundant expression and hemimethylation of C19MC in cell cultures from placenta-derived stromal cells. Biochem Biophys Res Commun 422:411-416.

  • Helmke BM, Markowski DN, Meyer A, Bullerdiek J (2012). The expression of HMGA2 varies strongly among colon carcinomas. Anticancer Res 32:1589-1593.

  • Kiefer Y, Schulte C, Tiemann M, Bullerdiek J (2012). Chronic lymphocytic leukemia-associated chromosomal abnormalities and miRNA deregulation. Appl Clin Genet 5:21-28.
  • Klemke M, Drieschner N, Belge G, Burchardt K, Junker K, Bullerdiek J (2012). Detection of PAX8-PPARG fusion transcripts in archival thyroid carcinoma samples by conventional RT-PCR. Genes Chromosomes Cancer 51:402-408.

  • Markowski DN., Bartnitzke S, Löning T, Drieschner N, Helmke BM, Bullerdiek J. (2012). MED12 mutations in uterine fibroids-their relationship to cytogenetic subgroups. Int J Cancer 131:1528-1536.

  • Markowski DN, Helmke BM, Radtke A, Froeb J, Belge G, Bartnitzke S, Wosniok W, Czybulka-Jachertz I, Deichert U, Bullerdiek J (2012). Fibroid explants reveal a higher sensitivity against MDM2-inhibitor nutlin-3 than matching myometrium. BMC Womens Health 12: 2.

  • Mohamed SA, Radtke A, Saraei R, Bullerdiek J, Sorani H, Nimzyk R, Karluss A, Sievers HH, Belge G (2012). Locally different endothelial nitric oxide synthase protein levels in ascending aortic aneurysms of bicuspid and tricuspid aortic valve. Cardiol Res Pract 2012:165957.
  • Müller MH, Reimann-Berg N, Bullerdiek J, Murua Escobar H (2012). Genetic characterization of dogs via chromosomal analysis and array-based comparative genomic hybridization (aCGH). Tierärztl Prax Ausg K Kleintiere Heimtiere 40:55-58.

  • Prabhune M, Belge G, Dotzauer A, Bullerdiek J, Radmacher M (2012). Comparison of mechanical properties of normal and malignant thyroid cells. Micron 43:1267-1272.
  • Reimann-Berg N, Bullerdiek J, Murua Escobar H, Nolte I (2012). Chromosomenuntersuchungen bei Hunden (Chromosome analyses in dogs). Tierärztl Prax Ausg K Kleintiere Heimtiere 40:191-196. 

  • Rippe V, Flor I, Debler JW, Drieschner N, Rommel B, Krause D, Junker K, Bullerdiek J (2012). Activation of the two microRNA clusters C19MC and miR-371-3 does not play prominent role in thyroid cancer. Mol Cytogenet 5:40.
  • Sendt W, Rippe V, Flor I, Drieschner N, Bullerdiek J (2012). Monosomy and ring chromosome 13 in a thyroid nodular goiter-do we underestimate its relevance in benign thyroid lesions? Cancer Genet 205:128-130. 

  • Sterenczak KA, Meier, M, Glage S, Meyer M, Willenbrock S, Wefstaedt P, Dorsch M, Bullerdiek J, Murua Escobar H, Hedrich H, Nolte I (2012). Longitudinal MRI contrast enhanced monitoring of early tumour development with manganese chloride (MnCl2) and superparamagnetic iron oxide nanoparticles (SPIOs) in a CT1258 based in vivo model of prostate cancer. BMC Cancer 12: 284.
  • Willenbrock S, Braun O, Baumgart J, Lange S, Junghanss C, Heisterkamp A, Nolte I, Bullerdiek J, Murua Escobar H (2012)(online 2011). TNF-α induced secretion of HMGB1 from non-immune canine mammary epithelial cells (MTH53A). Cytokine 57:210-220.



2011

  • Belge G, Radtke A, Meyer A, Stegen I, Richardt D, Nimzyk R, Nigam V, Dendorfer A, Sievers HH, Tiemann M, Buchwalow I, Bullerdiek J, Mohamed SA (2011). Upregulation of the high mobility group AT-hook 2 gene in acute aortic dissection is potentially associated with endothelial-mesenchymal transition. Histol Histopathol 26:1029-1037.

  • Bullerdiek J, Müsebeck J (2011). Prädiktive Diagnostik erblicher Tumordispositionen. Bremer Ärztejournal 64:13-14.

  • Drieschner N, Rippe V, Laabs A, Dittberner L, Nimzyk R, Junker K, Rommel B, Kiefer Y, Belge G, Bullerdiek J, Sendt W (2011). Interphase fluorescence in situ hybridization analysis detects a much higher rate of thyroid tumors with clonal cytogenetic deviations of the main cytogenetic subgroups than conventional cytogenetics. Cancer Genet 204:366-374.

  • Helmke BM, Markowski, DN, Müller MH, Sommer A, Müller J, Möller C, Bullerdiek J (2011). HMGA proteins regulate the expression of FGF2 in uterine fibroids.  Mol Hu. Repro. 17:135-142.

  • Klemke M, Drieschner N, Laabs A, Rippe V, Belge G, Bullerdiek J, Sendt W (2011). On the prevalence of the PAX8-PPARG fusion resulting from the chromosomal translocation t(2;3)(q13;p25) in adenomas of the thyroid. Cancer Genet 204:334-339.

  • Kloth L, Belge G, Burchardt K, Loeschke S, Wosniok W, Fu X, Mohamed SA, Drieschner N, Rippe V, Bullerdiek J (2011). Decrease in thyroid adenoma associated (THADA) expression is a marker of dedifferentiation of thyroid tissue. BMC Clin Pathol 11:13.
  • Markowski DN, Helmke BM, Belge G, Nimzyk R, Bartnitzke S, Deichert U, Bullerdiek J (2011). HMGA2 and p14Arf: major roles in cellular senescence of fibroids and therapeutic implications. Anticancer Res 31:753-761.

  • Markowski DN, Helmke BM, Meyer F, von Ahsen I, Nimzyk R, Nolte I, Bullerdiek J (2011). BMP4 increases expression of HMGA2 in mesenchymal stem cells. Cytokine 56:811-816.

  • Markowski, DN, Winter N, Meyer F, von Ahsen I, Wenk H, Nolte I, Bullerdiek J (2011). p14(Arf) acts as an antagonist of HMGA2 in senescence of mesenchymal stem cells-implications for benign tumorigenesis. Genes Chromosomes Cancer 50:489-498.

  • Reimann-Berg N, Murua Escobar H, Kiefer Y, Mischke R, Willenbrock S, Eberle N, Nolte I, Bullerdiek J (2011). Cytogenetic analysis of CpG-oligonucleotide DSP30 plus Interleukin-2-stimulated canine B-Cell lymphoma cells reveals the loss of one X chromosome as the sole abnormality.Cytogenet Genome Res 135:79-82. 

  • Reimann-Berg N, Willenbrock S, Murua Escobar H, Eberle N, Gerhauser I, Mischke R, Bullerdiek J, Nolte I (2011). Two new cases of polysomy 13 in canine prostate cancer. Cytogenet Genome Res 132:16-21.

  • Richter A, Lübbing M, Frank H-G, Nolte I, Bullerdiek J, von Ahsen I (2011). High-mobility group protein HMGA2-derived fragments stimulate the proliferation of chondrocytes and adipose tissue-derived stem cells. Eur Cell Mater 21:355-363.

  • Sterenczak KA, Kleinschmidt S, Wefstaedt P, Eberle N, Hewicker-Trautwein M, Bullerdiek J, Nolte I, Murua Escobar H (2011). Quantitative PCR and immunohistochemical analyses of HMGB1 and RAGE expression in canine disseminated histiocytic sarcoma (malignant histiocytosis). Anticancer Res 31: 1541-1548.

  • Winter N, Nimzyk R, Bösche C, Meyer A, Bullerdiek J. (2011). Chromatin immunoprecipitation to analyze DNA binding sites of HMGA2. PLoS One 6: e18837.  


2010
  • Bullerdiek J, Rommel B (2010). Comment Re: HMGA2 is a negative regulator of DNA-PK pathway. Cancer Res. 10:1742.
  • Gentschev I, Ehrig K, Donat U, Hess M, Rudolph S, Chen N, Yu YA, Zhang Q, Bullerdiek J, Nolte I, Stritzker J, Szalay AA(2010). Significant growth inhibition of canine mammary carcinoma xenografts following treatment with oncolytic vaccinia virus GLV-1h68. J Oncol 2010:736907.

  • Hashemi Nezhad M, Drieschner N, Helms S, Meyer A, Tadayyon M, Klemke M, Belge G, Bartnitzke S, Burchardt K, Frantzen C, Schmidt EH, Bullerdiek J (2010). 6p21 rearrangements in uterine leiomyomas targeting HMGA1. Cancer Genet Cytogenet 203:247-252.

  • Joetzke AE, Sterenczak KA, Eberle N, Wagner S, Soller JT, Nolte I, Bullerdiek J, Murua Escobar H, Simon D (2010). Expression of the high mobility group A1 (HMGA1) and A2 (HMGA2) genes in canine lymphoma: analysis of 23 cases and comparison to control cases.Vet Comp Oncol 8:87-95.

  • Kiefer Y, Drieschner N, Förster H, Tiemann M, Schulte C, Rommel B, Bullerdiek J (2010). An unbalanced t(15;18)(q21-q22;p11) as the sole cytogenetic aberration in a patient with B-cell chronic lymphocytic leukemia.Cancer Genet Cytogenet 200:65-69.

  • Klemke M, Meyer A, Hashemi Nezhad M, Belge G, Bartnitzke S, Bullerdiek J (2010). Loss of let-7 binding sites resulting from truncations of the 3' untranslated region of HMGA2 mRNA in uterine leiomyomas. Cancer Genet. Cytogenet 196:119-123.

  • Markowski DN, Bartnitzke S, Belge G, Drieschner N, Helmke BM, Bullerdiek J (2010). Cell culture and senescence in uterine fibroids.Cancer Genet Cytogenet 202:53-57.

  • Markowski DN, Helmke BM, Bullerdiek J (2010). Cellular senescence in usual type uterine leiomyoma. Fertil Steril 94: e79.

  • Markowski DN, von Ahsen I, Hashemi Nezhad M, Wosniok W, Helmke BM, Bullerdiek J (2010). HMGA2 and the p19Arf-TP53-CDKN1A axis: a delicate balance in the growth of uterine leiomyomas.Genes Chromosomes Cancer 49:661-668.
  • Meyer A, Eberle N, Bullerdiek J, Nolte I, Simon D (2010). High-mobility group B1 proteins in canine lymphoma: prognostic value of initial and sequential serum levels in treatment outcome following combination chemotherapy.Vet Comp Oncol 8:127-137.

  • Mohamed SA, Misfeld M, Hanke T, Charitos EI, Bullerdiek J, Belge G, Kuehnel W, Sievers HH (2010). Inhibition of caspase-3 differentially affects vascular smooth muscle cell apoptosis in the concave versus convex aortic sites in ascending aneurysms with a bicuspid aortic valve.Ann Anat. 192:145-150.
  • Rippe V, Dittberner L, Lorenz VN, Drieschner N, Nimzyk R, Sendt W, Junker K, Belge G, Bullerdiek J (2010). The two stem cell microRNA gene clusters C19MC and miR-371-3 are activated by specific chromosomal rearrangements in a subgroup of thyroid adenomas.PLoS One 5:e9485.

  • Sterenczak KA, Joetzke AE, Willenbrock S, Eberle N, Lange S, Junghanss C, Nolte I, Bullerdiek J, Simon D, Murua Escobar H. (2010 ). High-mobility group B1 (HMGB1) and receptor for advanced glycation end-products (RAGE) expression in canine lymphoma. Anticancer Res 30:5043-5048.





Top